Septerna (SEPN) risk factors

97 risks, 7 new, 8 dropped, 16 reworded since the prior year. Septerna added critical disclosures regarding U.S. government shutdowns affecting the FDA and SEC, reliance on Chinese suppliers like WuXi, and potential patent infringement risks. The company noted specific exposures including hypoparathyroidism treatments and collaborations with Novo.

98 risks. Septerna is a clinical-stage biotechnology company with 75 employees, focusing on endocrinology, immunology, and neurology programs like SEP-786. The company faces high regulatory hurdles, intense competition, and relies entirely on external funding and partnerships since generating no product revenue.